Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of NewAmsterdam Pharma Company NV (NASDAQ: NAMS) was $15.81 for the day, down -12.17% from the previous closing price of $18.00. In other words, the price has decreased by -$12.17 from its previous closing price. On the day, 2.06 million shares were traded. NAMS stock price reached its highest trading level at $18.0 during the session, while it also had its lowest trading level at $15.43.
Ratios:
Our analysis of NAMS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.08 and its Current Ratio is at 8.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $48.
On March 14, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $35.Scotiabank initiated its Sector Outperform rating on March 14, 2024, with a $35 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 26 ’25 when Topper James N bought 1,135 shares for $22.49 per share. The transaction valued at 25,521 led to the insider holds 3,013,569 shares of the business.
Michael H. Davidson bought 12,258 shares of NAMS for $286,960 on Mar 26 ’25. On Mar 26 ’25, another insider, Douglas F Kling, who serves as the Affiliate of the company, bought 16,539 shares for $23.41 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 1736222592 and an Enterprise Value of 902477632. For the stock, the TTM Price-to-Sale (P/S) ratio is 38.11 while its Price-to-Book (P/B) ratio in mrq is 2.26. Its current Enterprise Value per Revenue stands at 19.807 whereas that against EBITDA is -5.123.
Stock Price History:
The Beta on a monthly basis for NAMS is 0.06, which has changed by -0.1937787 over the last 52 weeks, in comparison to a change of -0.024663687 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $15.19. The 50-Day Moving Average of the stock is -25.45%, while the 200-Day Moving Average is calculated to be -21.36%.
Shares Statistics:
NAMS traded an average of 945.76K shares per day over the past three months and 1362300 shares per day over the past ten days. A total of 108.06M shares are outstanding, with a floating share count of 57.00M. Insiders hold about 48.10% of the company’s shares, while institutions hold 48.02% stake in the company. Shares short for NAMS as of 1741910400 were 4342156 with a Short Ratio of 4.59, compared to 1739491200 on 2911595. Therefore, it implies a Short% of Shares Outstanding of 4342156 and a Short% of Float of 5.9499998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
